Barclays Maintains an 'Equalweight' on Brooks Automation (BRKS); Expanding Its Life Sciences Portfolio

Barclays maintains an 'Equalweight' on Brooks Automation Inc. (NASDAQ: BRKS) price target of $12.00.

Barclays analyst says, "We Believe It's Too Early To Get Excited About Life Sciences Opportunity, See Better Upside Elsewhere: While management is progressing rapidly with its diversification strategy, we believe it's too early to get excited about the Life Sciences market opportunity. We maintain our 2-Equal Weight rating, as we see better upside elsewhere in MKS Instruments (Nasdaq: MKSI), where management's diversification efforts are coupled with a shareholder-friendly cash return strategy, including a 2.2% dividend yield and potential for share buybacks."

"We Maintain Our Estimates Pending Guidance on Acquisition's Forward Revenue/Margin Implications: Without clarity on the expected revenue and margin implications over the next 1-2 years, we maintain our CY11estimates of $682M/$1.40 (consensus $681M/$1.48) and CY12 of $614M/$1.25 (consensus NA)."

For more ratings news on Brooks Automation Inc. click here and for the rating history of Brooks Automation Inc. click here.

Shares of Brooks Automation Inc. closed at $10.60 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
• Beike (BEKE) PT Raised to $23 at Morgan Stanley